PMC6637684_01
Cutaneous lesions located in left costal dermatome, characterized by multiple necrotic lesions.
CRII2019-6357256.001.jpg
PMC6637684_01_CRII2019-6357256.001.jpg
fig1
The patient received twelve doses of efalizumab, but the drug was suspended due to herpes zoster dermatitis (Figure 1), and treatment with acyclovir was indicated with adequate clinical response.
Comparison between CRP levels during application of omalizumab. The variation of protein levels does not correlate with the clinical manifestations of the patient and IgE levels.
CRII2019-6357256.002.jpg
PMC6637684_01_CRII2019-6357256.002.jpg
fig2
The variations of CRP (C-reactive protein) do not correlate with the clinical manifestations of the patient and IgE levels (Figures 2 and 3).
Comparison between IgE levels during application of omalizumab. The y-axis: serum IgE expressed in IU/ml; the x-axis: the dates on which these levels were taken. The decrease in IgE levels was clearly observed during the application of omalizumab; these increased after treatment was discontinued.
CRII2019-6357256.003.jpg
PMC6637684_01_CRII2019-6357256.003.jpg
fig3
The variations of CRP (C-reactive protein) do not correlate with the clinical manifestations of the patient and IgE levels (Figures 2 and 3).